Relmada Therapeutics, Inc.

RLMD · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$10,091-$9,866-$17,559-$18,657
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$3,608$3,473$4,481$6,718
Change in WC$4,717$25-$4,770$2,903
Other Non-Cash-$4,955-$33-$219$236
Operating Cash Flow-$6,722-$6,402-$18,067-$8,800
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$234-$321-$488-$655
Inv. Sales/Matur.$6,987$7,000$15,848$12,000
Other Inv. Act.$0$0$0$0
Investing Cash Flow$6,753$6,679$15,360$11,345
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$0$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0-$73$0-$172
Financing Cash Flow$0-$73$0-$172
Forex Effect$0$0$0$0
Net Chg. in Cash$31$204-$2,707$2,373
Supplemental Information
Beg. Cash$1,353$1,150$3,857$1,484
End Cash$1,384$1,353$1,150$3,857
Free Cash Flow-$6,722-$6,402-$18,067-$8,800